Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biotechnology Assets's Enterprise Value is €26.45 Mil.
Biotechnology Assets's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €2.63 Mil. Therefore, Biotechnology Assets's EV-to-EBIT ratio for today is 10.05.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Biotechnology Assets's Enterprise Value is €26.45 Mil.
Biotechnology Assets's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €5.10 Mil. Therefore, Biotechnology Assets's EV-to-EBITDA ratio for today is 5.19.
Biotechnology Assets Enterprise Value Historical Data
The historical data trend for Biotechnology Assets's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biotechnology Assets's Enterprise Value
For the Biotechnology subindustry, Biotechnology Assets's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotechnology Assets's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Biotechnology Assets's Enterprise Value falls into.
Biotechnology Assets Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Biotechnology Assets's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotechnology Assets (XMAD:BST) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Biotechnology Assets's current Enterprise Value is €26.45 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biotechnology Assets's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €2.63 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Biotechnology Assets's current Enterprise Value is €26.45 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biotechnology Assets's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €5.10 Mil.
Biotechnology Assets's current Enterprise Value is €26.45 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Biotechnology Assets's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €3.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotechnology Assets Enterprise Value Related Terms
Thank you for viewing the detailed overview of Biotechnology Assets's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Biotechnology Assets (XMAD:BST) Business Description
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XMAD:BST has been successfully added to your 